首页> 美国卫生研究院文献>Kidney Research and Clinical Practice >Hemodialysis as a life-sustaining treatment at the end of life
【2h】

Hemodialysis as a life-sustaining treatment at the end of life

机译:血液透析是生命终结时的维持生命的治疗

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The Act on Decisions on Life-Sustaining Treatment for Patients in Hospice and Palliative Care or at the End of Life came into effect on February 4th, 2018, in South Korea. Based on the Act, all Koreans over the age of 19 years can decide whether to refuse life-sustaining treatments at the end of life via advance directive or physician orders. Hemodialysis is one of the options designated in the Act as a life-sustaining treatment that can be withheld or withdrawn near death. However, hemodialysis has unique features. So, it is not easy to determine the best candidates for withholding/withdrawing hemodialysis at the end of life. Thus, it is necessary to investigate the meaning and implications of hemodialysis at the end of life with ethical consideration of futility and withholding or withdrawal of intervention.
机译:《关于临终关怀和姑息治疗或临终患者维持生命治疗的决定法》于2018年2月4日在韩国生效。根据该法案,所有19岁以上的韩国人都可以通过预先指示或医生命令决定是否在生命终了时拒绝维持生命的治疗。血液透析是该法案中指定的一种可以维持生命的治疗方法,可以在死亡时将其撤回或撤回。但是,血液透析具有独特的功能。因此,要确定在生命终结时停止/退出血液透析的最佳人选并不容易。因此,有必要从道德上考虑徒劳无功以及拒绝或撤回干预措施,来研究血液透析终生的意义和含义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号